Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iSERA LifesciencesBOM:534920 20 Return-on-Tangible-Equity is 26.67% as of Mar. 2026. GuruFocus rates BOM:534920 with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 2,484 Software companies, iSERA Lifesciences ranks better than 50.04% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. iSERA Lifesciences's annualized net income for the quarter that ended in Mar. 2026 was ₹21.99 Mil. iSERA Lifesciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹82.47 Mil. Therefore, iSERA Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 26.67%.
The historical rank and industry rank for iSERA Lifesciences's Return-on-Tangible-Equity or its related term are showing as below:
BOM:534920'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -129.98 Med: -0.77 Max: 56504.76
Current: 9.68
During the past 13 years, iSERA Lifesciences's highest Return-on-Tangible-Equity was 56,504.76%. The lowest was -129.98%. And the median was -0.77%.
BOM:534920's Return-on-Tangible-Equity is ranked better than 50.04% of 2484
companies
in the Software industry
Industry Median: 9.64
vs BOM:534920: 9.68
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
iSERA Lifesciences Return-on-Tangible-Equity Related Terms
iSERA Lifesciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for iSERA Lifesciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:534920 vs IBM, ACN, FISV: Return-on-Tangible-Equity Comparison
For the Information Technology Services subindustry, iSERA Lifesciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iSERA Lifesciences Return-on-Tangible-Equity vs Software Industry
For the Software industry and Technology sector, iSERA Lifesciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where iSERA Lifesciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 26.67% mean?
iSERA Lifesciences (BOM:534920) has a Return-on-Tangible-Equity of 26.67% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on iSERA Lifesciences and its competitors. According to the industry distribution chart, iSERA Lifesciences ranks #1241 out of 2484 companies in the Software industry, placing it in the top 50%.
Is iSERA Lifesciences' Return-on-Tangible-Equity too high?
iSERA Lifesciences' current Return-on-Tangible-Equity is 26.67%. The Software industry median Return-on-Tangible-Equity is 9.64. iSERA Lifesciences' value of 26.67% is 176.7% above this industry median. Based on the distribution chart, iSERA Lifesciences ranks #1241 out of 2484 companies in the Software industry, which is above the industry midpoint. Overall, iSERA Lifesciences has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does iSERA Lifesciences' Return-on-Tangible-Equity compare to IBM and ACN?
According to the Software industry distribution chart, iSERA Lifesciences ranks #1241 out of 2484 companies for Return-on-Tangible-Equity. This puts iSERA Lifesciences in the upper half of its industry. The industry median Return-on-Tangible-Equity is 9.64. iSERA Lifesciences' value of 26.67% is 176.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Software company?
The median Return-on-Tangible-Equity among Software companies is 9.64, based on 2,484 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iSERA Lifesciences's current Return-on-Tangible-Equity of 26.67% is 176.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on iSERA Lifesciences and its competitors. For the Software industry, the median Return-on-Tangible-Equity is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iSERA Lifesciences's current Return-on-Tangible-Equity is 26.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iSERA Lifesciences stock overvalued right now?
iSERA Lifesciences (BOM:534920) has a current Return-on-Tangible-Equity of 26.67%. The current Return-on-Tangible-Equity is 26.67% and 176.7% above the Software industry median of 9.64. iSERA Lifesciences' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For iSERA Lifesciences (BOM:534920), the current Return-on-Tangible-Equity is 26.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iSERA Lifesciences Ltd, formally known as Covidh Technologies Ltd, is a technology services provider. The company provides IT and IT-enabled services. It derives revenue majorly from the sale of IT and IT-enabled services and Hardware.
20GF Score
Get the complete analysis for BOM:534920
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:534920 has been successfully added to your 
